Champions Oncology Inc Dossier
Qualitative Analysis
Business overview
Champions Oncology, Inc. (NASDAQ: CSBR) is a leading translational oncology research organization and contract research organization (CRO). The company specializes in providing end-to-end preclinical and clinical research services to pharmaceutical and biotechnology organizations globally. Its core technology platform, TumorGraft, utilizes a highly annotated, molecularly characterized living bank of over 1,400 patient-derived xenograft (PDX) and primary hematological malignancy models to personalize cancer care and accelerate drug discovery. Additionally, Champions offers advanced clinical specialty testing (such as high-complexity flow cytometry, next-generation sequencing, and histology) and leverages its Lumin Bioinformatics platform to deliver multi-omics data-driven software solutions.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning previously outsourced radiolabeling laboratory work into Champions Oncology's own internal laboratories.
Expected impact: Reduction in cost of sales and improvement in gross margins.
Advancing therapeutic programs and target discovery through its wholly owned subsidiary, Corellia AI, which leverages AI-enabled workflows and Champions' deep cancer datasets.
Expected impact: Development of innovative first-in-class Antibody Drug Conjugates (ADCs) and long-term pipeline acceleration.
Expanding the proprietary database of patient-derived xenograft (PDX) models and primary hematological malignancy models through clinical networks and research collaborations.
Expected impact: Strengthens the core translational oncology solutions and drives data licensing revenue streams.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Combines MDC's translational imaging and radiochemistry expertise with Champions Oncology's patient-derived tumor models to accelerate the development of targeted radionuclide therapies and radiopharmaceutical therapeutics.
Terms: Not disclosed
Combines Champions' patient-sourced cancer models with TransCure's full human immune system mouse models to offer European customers localized PDX studies and pharmacology work, reducing intercontinental logistics.
Terms: Not disclosed